Blood‑based biomarkers are gaining attention as a way to spot Alzheimer disease pathology before symptoms appear, prompting clinicians to consider how early detection could affect treatment choices and care planning.
New Study Shows P‑tau217 Blood Test Matches PET Scans
At the 2026 Alzheimer’s Association International Conference, researchers presented data on a blood assay measuring phosphorylated tau 217 (P‑tau217). The analysis used two independent cohorts – the Bio‑Hermes study and pooled Lilly cohorts – and compared results to amyloid PET imaging, the current reference standard for detecting amyloid plaques.
The test demonstrated strong rule‑in performance, with positive predictive values exceeding 83 percent. In addition, the assay’s accuracy was non‑inferior to quantitative amyloid PET, suggesting that a simple blood draw could provide comparable diagnostic information.
These findings could shift the diagnostic pathway, especially for cognitively unimpaired individuals who might otherwise be screened only after noticeable decline.
Related: User access denied after block
Clinical Implications Discussed by Iowa Specialist
Yogesh Shah, MD, MPH, FAAFP, medical director of the Broadlawns Memory Clinic, addressed the practical impact of earlier identification during a NeurologyLive® Special Report. He highlighted that dementia often goes undiagnosed early, noting that roughly half of patients with moderate Alzheimer disease and up to 90 percent of those with mild cognitive impairment remain unidentified.
Shah pointed to several barriers: primary‑care providers may not prioritize diagnosis, there has been a lack of simple diagnostic tools, and many patients assume little can be done once symptoms appear. “Patients view this as their fate and don’t feel there’s much within their control,” he said.
He argued that the new blood test could change that situation. With a reliable, minimally invasive assay, clinicians could diagnose patients sooner, allowing individuals to participate actively in their care plans. Early diagnosis enables discussions about power of attorney, legal documents, and potential enrollment in disease‑modifying therapies already available in the United States.
Beyond treatment options, the specialist emphasized risk‑reduction strategies. A Lancet study identified 14 modifiable risk factors that span the lifespan, from teenage years to later adulthood. Addressing these factors could lower dementia risk by up to 45 percent, according to the study.
Related: Global Issues Dominate World News This Week
While the data are promising, the rollout of blood‑based testing will require education for both providers and patients. “Hopefully, patients will hear about these new tests. Hopefully, physicians and other providers will hear about these tests and begin using them in their clinics,” Shah said, emphasizing the need for broader awareness.
Early detection may give patients more agency, allowing them to decide how much involvement they want in treatment decisions and lifestyle changes.
One cautious observation is that the success of such screening will depend on health‑system capacity to follow up positive results with confirmatory imaging or specialist referral. If the infrastructure cannot keep pace, the benefit of early identification might be uneven across populations.
The conference coverage was produced independently by Neurology Live and supported by Eli Lilly and Company, which had no direct influence on the content.